BR112015027699A2 - Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico - Google Patents

Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico

Info

Publication number
BR112015027699A2
BR112015027699A2 BR112015027699A BR112015027699A BR112015027699A2 BR 112015027699 A2 BR112015027699 A2 BR 112015027699A2 BR 112015027699 A BR112015027699 A BR 112015027699A BR 112015027699 A BR112015027699 A BR 112015027699A BR 112015027699 A2 BR112015027699 A2 BR 112015027699A2
Authority
BR
Brazil
Prior art keywords
therapeuticly
robenidine
acceptable salt
medical device
pharmaceutical composition
Prior art date
Application number
BR112015027699A
Other languages
English (en)
Other versions
BR112015027699B1 (pt
Inventor
Page Stephen
Garg Sanjay
Original Assignee
Neoculi Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013901517A external-priority patent/AU2013901517A0/en
Application filed by Neoculi Pty Ltd filed Critical Neoculi Pty Ltd
Publication of BR112015027699A2 publication Critical patent/BR112015027699A2/pt
Publication of BR112015027699B1 publication Critical patent/BR112015027699B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

USO DE ROBENIDINA OU UM SAL TERAPEUTICAMENTE ACEITÁVEL DA MESMA, COMPOSIÇÃO FARMACÊUTICA ANTIBACTERIANA E DISPOSITIVO MÉDICO. A invenção compreende métodos para o tratamento e prevenção de uma infecção bacteriana num sujeito, métodos para a preparação de um medicamento para utilização no tratamento e prevenção de uma infecção bacteriana num sujeito, e composições farmacêuticas e veterinárias antibacterianas quando utilizados neste documento.
BR112015027699-7A 2013-05-01 2014-05-01 Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico BR112015027699B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013901517A AU2013901517A0 (en) 2013-05-01 Methods of Treating Bacterial Infections
AU2013901517 2013-05-01
PCT/AU2014/000480 WO2014176634A1 (en) 2013-05-01 2014-05-01 Methods for treating bacterial infections

Publications (2)

Publication Number Publication Date
BR112015027699A2 true BR112015027699A2 (pt) 2017-08-29
BR112015027699B1 BR112015027699B1 (pt) 2021-11-30

Family

ID=51842982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027699-7A BR112015027699B1 (pt) 2013-05-01 2014-05-01 Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico

Country Status (10)

Country Link
US (2) US9539223B2 (pt)
EP (1) EP2991638B1 (pt)
JP (2) JP6254257B2 (pt)
CN (2) CN105358141A (pt)
AU (1) AU2014262127B2 (pt)
BR (1) BR112015027699B1 (pt)
CA (1) CA2910752C (pt)
NZ (1) NZ713615A (pt)
RU (1) RU2666605C2 (pt)
WO (1) WO2014176634A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64862B1 (sr) 2012-03-19 2023-12-29 Cidara Therapeutics Inc Dozni režimi za jedinjenja klase ehinokandina
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CA2960331A1 (en) 2014-09-12 2016-03-17 Antibiotx Aps Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105030744B (zh) * 2015-07-09 2019-04-19 广州英赛特生物技术有限公司 取代苯胍衍生物作为多粘菌素类抗生素增效剂的应用
JP2017055716A (ja) * 2015-09-17 2017-03-23 国立大学法人名古屋大学 多剤耐性菌スクリーニング用プレート、多剤耐性菌の検出方法、多剤耐性菌検出キットおよび多剤耐性菌スクリーニング用液体培地
CN105368752A (zh) * 2015-12-09 2016-03-02 哈尔滨医科大学 一株从人体肠道中分离的能产生抗癌活性代谢产物的细菌ad05及其用途
EP3399995A4 (en) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. METHODS FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
EP3423159A4 (en) * 2016-03-02 2019-11-06 Anacor Pharmaceuticals, Inc. BORN SMALL MOLECULES
EP3971191A1 (en) * 2016-03-02 2022-03-23 Bill And Melinda Gates Foundation Boron-containing small molecules
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN107629977A (zh) * 2016-07-18 2018-01-26 广州普维君健药业有限公司 脆弱拟杆菌在制备防治副溶血弧菌感染的组合物中的应用
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
CN106771190B (zh) * 2016-12-26 2018-11-13 中国农业科学院兰州兽医研究所 一种羊无浆体病间接elisa诊断试剂盒及其制备方法
CN106727326A (zh) * 2016-12-31 2017-05-31 河南牧翔动物药业有限公司 一种喹羟酮脂质体及其制备方法
PE20191785A1 (es) * 2017-03-16 2019-12-24 Microsintesis Inc Composiciones y metodos que involucran moleculas probioticas
CN109200063A (zh) * 2017-06-29 2019-01-15 中山大学 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用
WO2019014333A1 (en) 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
WO2019151371A1 (ja) * 2018-01-31 2019-08-08 ニュートリー株式会社 肺炎球菌感染症の予防及び／又は治療剤
GB201804165D0 (en) * 2018-03-15 2018-05-02 Assure Medical Ltd Urethal delivery device
JP7032216B2 (ja) * 2018-04-04 2022-03-08 株式会社日立ハイテク 細菌検査装置および細菌検査方法
WO2019199496A1 (en) * 2018-04-12 2019-10-17 Purdue Research Foundation Benzamide antibacterial agents
CN108660229B (zh) * 2018-05-25 2022-06-21 上海交通大学医学院附属上海儿童医学中心 评价脓毒症的生物标志物
CN108753646B (zh) * 2018-06-12 2021-10-22 上海交通大学医学院附属仁济医院 一株对革兰阳性耐药菌具有广谱抗菌活性的人葡萄球菌及其筛选方法和应用
CN109321636A (zh) * 2018-10-09 2019-02-12 中国农业大学 一种用于衣原体种特异性检测的芯片及应用
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
WO2020252131A1 (en) * 2019-06-12 2020-12-17 Ausubel Frederick M Antibiotic compounds
WO2021001986A1 (ja) 2019-07-04 2021-01-07 株式会社ソーシン 動物用の口腔用組成物並びにそれを使用した動物用の歯周病予防剤、感染症予防剤及び口臭予防剤
CN110964668B (zh) * 2019-12-26 2021-05-04 浙江大学 抗大肠杆菌蜂房芽孢杆菌菌株及其在化妆品中的防腐应用
CN111100821B (zh) * 2020-01-16 2023-07-14 沈阳医学院 一种链球菌及其应用
WO2021212181A1 (en) * 2020-04-24 2021-10-28 Neoculi Pty Ltd Methods and compositions for treating fungal infections
CN111505299B (zh) * 2020-04-29 2022-09-06 上海理工大学 一种人葡萄球菌免疫胶体金快速检测试纸条
CN112053744A (zh) * 2020-07-23 2020-12-08 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） 一种基于cgMLST的变异链球菌分型方法
CN111870594B (zh) * 2020-08-27 2022-03-22 首都医科大学附属北京胸科医院 苯乙肼在制备抗偶发分枝杆菌感染的药物中的应用
CN112322556B (zh) * 2020-12-07 2022-02-18 济南航晨生物科技有限公司 耐受高盐环境的尼泊尔葡萄球菌及培养方法
CN112795672A (zh) * 2021-02-07 2021-05-14 佛山科学技术学院 引物组及多重pcr检测体系
CN113337436A (zh) * 2021-06-09 2021-09-03 中国科学院新疆生态与地理研究所 一种尿素分解菌及其选育方法和应用
CN113462739A (zh) * 2021-07-01 2021-10-01 中山大学 一种检测促进抗生素杀菌效率提高的物质的方法和试剂盒
CN114058551B (zh) * 2021-12-03 2023-07-25 楚雄云泉酱园有限责任公司 一种用于豆瓣酱发酵的琥珀葡萄球菌
CN114525225B (zh) * 2022-03-04 2023-11-24 中国水产科学研究院北戴河中心实验站 一种对鱼类具有强致病力和强耐药性的黏质沙雷氏菌yp1和应用
CN114507628B (zh) * 2022-03-30 2023-04-18 昆明理工大学 一株马胃葡萄球菌fs310及其应用
WO2023212291A1 (en) * 2022-04-29 2023-11-02 Virginia Tech Intellectual Properties, Inc. Treatment of pathogenic neisseria sp. infection with triazole antifungal agents
CN114774321B (zh) * 2022-05-07 2023-11-10 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 一种棒状杆菌及其在眼表抗真菌感染中的应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
CN115040506A (zh) * 2022-06-23 2022-09-13 四川农业大学 7-羟基香豆素在制备防治草鱼嗜水气单胞菌感染药剂中的应用
CN116121154B (zh) * 2023-04-10 2023-06-27 四川厌氧生物科技有限责任公司 一种乳明串珠菌及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL42800A (en) 1973-07-20 1976-03-31 Abic Ltd Water-soluble composition comprising a robenidine salt
IL46406A (en) 1975-01-08 1977-08-31 Abic Ltd The water-floating mixture containing robinidin
BR9914998A (pt) * 1998-11-03 2001-07-10 Pfizer Prod Inc Antibióticos macrólidos
US6599893B2 (en) * 2000-08-29 2003-07-29 Essential Therapeutics, Inc. Cephalosporin antibiotics and prodrugs thereof
JP2008514586A (ja) * 2004-09-27 2008-05-08 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 新規な抗菌剤
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
CA2717489A1 (en) * 2008-02-29 2009-09-24 Shinshu University Kit for detecting cancer cells metastasizing into sentinel lymph node
AU2009284136A1 (en) * 2008-08-18 2010-02-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Susceptibility to HSP90-inhibitors
FR2939447B1 (fr) * 2008-12-05 2011-01-07 Univ Aix Marseille Ii Milieu et procede de culture et d'identification des mycobacteries incluant les mycobacteries du complexe mycobacterium tuberculosis.

Also Published As

Publication number Publication date
CN112656782A (zh) 2021-04-16
RU2666605C2 (ru) 2018-09-11
BR112015027699B1 (pt) 2021-11-30
US20160058717A1 (en) 2016-03-03
EP2991638A1 (en) 2016-03-09
CA2910752C (en) 2021-11-23
JP6254257B2 (ja) 2017-12-27
JP2018058875A (ja) 2018-04-12
EP2991638B1 (en) 2019-06-26
WO2014176634A1 (en) 2014-11-06
US9775818B2 (en) 2017-10-03
NZ713615A (en) 2020-05-29
AU2014262127B2 (en) 2019-05-02
AU2014262127A1 (en) 2015-11-12
RU2015150263A (ru) 2017-06-06
JP2016520044A (ja) 2016-07-11
EP2991638A4 (en) 2016-12-28
CN105358141A (zh) 2016-02-24
US9539223B2 (en) 2017-01-10
CA2910752A1 (en) 2014-11-06
US20170071884A1 (en) 2017-03-16
RU2015150263A3 (pt) 2018-03-19

Similar Documents

Publication Publication Date Title
BR112015027699A2 (pt) Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
BR112014000665A2 (pt) composto, uso do mesmo, composição farmacêutica, agente antimicrobiano, e, método para previnir ou tratar uma infecção bacteriana
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112014022214A2 (pt) fenólicos antibacterianos
BR112015029367A8 (pt) combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
EA201692032A1 (ru) Антибактериальные соединения
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
BR112016029619A8 (pt) Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/05/2014, OBSERVADAS AS CONDICOES LEGAIS.